Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,608,504 papers from all fields of science
Search
Sign In
Create Free Account
CI 1040
Known as:
CI-1040
, CI1040
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
PD 184352
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
M. Huang
,
Jih-Hsiang Lee
,
+4 authors
J. Yang
Molecular oncology
2013
Corpus ID: 207016076
Highly Cited
2010
Highly Cited
2010
Shifting HIFs in osteoarthritis
M. Husa
,
R. Liu-Bryan
,
R. Terkeltaub
Nature Medicine
2010
Corpus ID: 11005246
There is no cure for osteoarthritis—the most common disease of the joints. By piecing together the molecular events that drive…
Expand
Highly Cited
2009
Highly Cited
2009
Simvastatin Inhibits Angiotensin II–Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E–Knockout Mice: Possible Role of ERK
Yali Zhang
,
Jack C Naggar
,
+4 authors
J. Galper
Arteriosclerosis, thrombosis, and vascular…
2009
Corpus ID: 33150300
Objective—Abdominal aortic aneurysm (AAA) is a life-threatening disease affecting almost 10% of the population over age 65…
Expand
Highly Cited
2008
Highly Cited
2008
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
A. Jimeno
,
A. Tan
,
+12 authors
M. Hidalgo
Cancer research
2008
Corpus ID: 23156300
The epidermal growth factor receptor (EGFR) inhibitor erlotinib is approved for treatment of pancreatic cancer but the overall…
Expand
Highly Cited
2008
Highly Cited
2008
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
S. Barrett
,
A. Bridges
,
+17 authors
H. Tecle
Bioorganic & medicinal chemistry letters
2008
Corpus ID: 206238341
Highly Cited
2007
Highly Cited
2007
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Dingxie Liu
,
Zhi Liu
,
David Jiang
,
A. Dackiw
,
M. Xing
The Journal of clinical endocrinology and…
2007
Corpus ID: 25343579
CONTEXT Targeting MAPK kinase (MEK) in the MAPK pathway is a potentially effective therapeutic strategy for thyroid cancer…
Expand
Highly Cited
2006
Highly Cited
2006
The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines
R. Mattingly
,
J. Kraniak
,
+6 authors
J. Reiners
Journal of Pharmacology and Experimental…
2006
Corpus ID: 34819504
Type 1 neurofibromatosis (NF1) is a common autosomal dominant disorder that results in neuroectodermal tumors. The NF1 tumor…
Expand
Highly Cited
2005
Highly Cited
2005
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
P. LoRusso
,
A. Adjei
,
+12 authors
M. Meyer
Journal of clinical oncology : official journal…
2005
Corpus ID: 22861458
PURPOSE This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD…
Expand
Highly Cited
2004
Highly Cited
2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
J. Rinehart
,
A. Adjei
,
+12 authors
M. Meyer
Journal of clinical oncology : official journal…
2004
Corpus ID: 8743649
PURPOSE This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral…
Expand
Review
2003
Review
2003
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
L. F. Allen
,
J. Sebolt-Leopold
,
M. Meyer
Seminars in oncology
2003
Corpus ID: 9216417
Several key growth factors, cytokines, and proto-oncogenes transduce their growth- and differentiation-promoting signals through…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE